A Phase 3, Clinical Pharmacology Study of TAK-438 (20 mg, 40 mg) in Patients with PPI-Resistant Erosive Esophagitis

Recruitment & Eligibility

Sex: All

Target Recruitment: 19

Inclusion Criteria

1.The participant has been treated with standard-dose or higher-than-standard-dose PPI until immediately before the start of the Observation Phase.
2.Outpatient (in principle)
3.At the endoscopy scheduled for the Observation Phase (Visit 2), the participant must have endoscopically confirmed reflux esophagitis of Grade A to D, as defined by the LA classification grading system, which remains insufficiently controlled with standard-dose or higher-than-standard-dose PPI therapy.
4.The participant showed good compliance to the study medication in the Observation Phase (compliance rate 80% or more).

Exclusion Criteria

1.Participants with an esophagus-related complication (eosinophilic esophagitis, esophageal varices, scleroderma, viral or fungal infection, esophageal stenosis, etc.), a history of radiotherapy or cryotherapy of the esophagus, a caustic or physiochemical trauma (esophageal sclerotherapy, etc.). However, participants with Schatzki's ring (mucosal tissue ring around inferior esophageal sphincter) or Barrett's esophagus are allowed to be included.
2.Participants who have received surgery or treatment affecting gastroesophageal reflux (cardioplasty, dilation of esophageal stenosis [excluding Schatzki's ring], etc.), or who have a history of surgery of stomach or duodenum (excluding removal of benign polyp under endoscopy)
3.Participants who have acute upper gastrointestinal bleeding, gastric or duodenal ulcer (mucosal defect with white coating) at the start of the Observation Phase (Visit 1) or at endoscopy during the Observation Phase (Visit 2). However, participants with gastric or duodenal erosions are allowed to be included.
4. Participants with a previous or current history of Zollinger-Ellison syndrome, or other gastric acid hypersecretion disorders.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Time-course of changes in 24-hour gastroesophageal pH.<br>Timeframe:Week 8<br>Gastric and esophageal pH4 HTR (pH 4 Holding Time Ratio) will be calculated based on 24-hour gastroesophageal pH monitoring.

Secondary Outcome Measures

Name	Time	Method
Endoscopic healing rate at Week 8 of erosive esophagitis<br>Timeframe:Week 8

Related Trials

To determine whether adding MLN9708 to the combination of lenalidomide and dexamethasone improves survival in patients with multiple myeloma whose disease is no longer responding or has not responded, to previous treatment.

Phase 1

Millennium Pharmaceuticals, Inc.

Updated 3/21/2022

To determine whether adding MLN9708 to the combination of lenalidomide and dexamethasone improves survival in patients with multiple myeloma whose disease is no longer responding or has not responded, to previous treatment.

Phase 1

Millennium Pharmaceuticals, Inc.

Updated 4/25/2022

A Phase 3, Double-Blind Study of TAK-438 (20 mg) in the Treatment of Erosive Esophagitis

Phase 3

TAKEDA PHARMACEUTICAL COMPANY LTD.

Updated 10/17/2023

To determine whether adding MLN9708 to the combination of lenalidomide and dexamethasone improves survival in patients with multiple myeloma whose disease is no longer responding or has not responded, to previous treatment.

Phase 1

Millennium Pharmaceuticals, Inc.

Updated 5/2/2022

To determine whether adding MLN9708 to the combination of lenalidomide and dexamethasone improves survival in patients with multiple myeloma whose disease is no longer responding or has not responded, to previous treatment.

Phase 1

Millennium Pharmaceuticals, Inc.

Updated 5/16/2022

Study to determine whether adding MLN9708 to the combination of lenalidomide and dexamethasone improves survival in patients who have been newly diagnosed with multiple myeloma and have not received previous anti-myeloma treatment

Phase 1

Millennium Pharmaceuticals, Inc.

Updated 4/19/2022

Study to determine whether adding MLN9708 to the combination of lenalidomide and dexamethasone improves survival in patients who have been newly diagnosed with multiple myeloma and have not received previous anti-myeloma treatment

Phase 1

Millennium Pharmaceuticals, Inc.

Updated 3/14/2022

To determine whether adding MLN9708 to the combination of lenalidomide and dexamethasone improves survival in patients with multiple myeloma whose disease is no longer responding or has not responded, to previous treatment.

Phase 1

Millennium Pharmaceuticals, Inc.

Updated 3/2/2022

To determine whether adding MLN9708 to the combination of lenalidomide and dexamethasone improves survival in patients with multiple myeloma whose disease is no longer responding or has not responded, to previous treatment.

Phase 1

Millennium Pharmaceuticals, Inc.

Updated 4/19/2022

To determine whether adding MLN9708 to the combination of lenalidomide and dexamethasone improves survival in patients with multiple myeloma whose disease is no longer responding or has not responded, to previous treatment.

Phase 1

Millennium Pharmaceuticals, Inc.

Updated 5/9/2022

A Phase 3, Clinical Pharmacology Study of TAK-438 (20 mg, 40 mg) in Patients with PPI-Resistant Erosive Esophagitis

Recruitment & Eligibility

Study & Design

Related Trials

To determine whether adding MLN9708 to the combination of lenalidomide and dexamethasone improves survival in patients with multiple myeloma whose disease is no longer responding or has not responded, to previous treatment.

To determine whether adding MLN9708 to the combination of lenalidomide and dexamethasone improves survival in patients with multiple myeloma whose disease is no longer responding or has not responded, to previous treatment.

A Phase 3, Double-Blind Study of TAK-438 (20 mg) in the Treatment of Erosive Esophagitis

To determine whether adding MLN9708 to the combination of lenalidomide and dexamethasone improves survival in patients with multiple myeloma whose disease is no longer responding or has not responded, to previous treatment.

To determine whether adding MLN9708 to the combination of lenalidomide and dexamethasone improves survival in patients with multiple myeloma whose disease is no longer responding or has not responded, to previous treatment.

Study to determine whether adding MLN9708 to the combination of lenalidomide and dexamethasone improves survival in patients who have been newly diagnosed with multiple myeloma and have not received previous anti-myeloma treatment

Study to determine whether adding MLN9708 to the combination of lenalidomide and dexamethasone improves survival in patients who have been newly diagnosed with multiple myeloma and have not received previous anti-myeloma treatment

To determine whether adding MLN9708 to the combination of lenalidomide and dexamethasone improves survival in patients with multiple myeloma whose disease is no longer responding or has not responded, to previous treatment.

To determine whether adding MLN9708 to the combination of lenalidomide and dexamethasone improves survival in patients with multiple myeloma whose disease is no longer responding or has not responded, to previous treatment.

To determine whether adding MLN9708 to the combination of lenalidomide and dexamethasone improves survival in patients with multiple myeloma whose disease is no longer responding or has not responded, to previous treatment.

Clinical Trial Alerts

Clinical Trial Alerts